GMAB Key Statistics, Chart & Performance
The current stock price of GMAB is 33.88 USD. In the past month the price increased by 0.68%. In the past year, price increased by 60.34%.
GMAB Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GMAB. When comparing the yearly performance of all stocks, GMAB is one of the better performing stocks in the market, outperforming 90.13% of all stocks.
GMAB Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to GMAB. GMAB has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
GMAB Financial Highlights
Over the last trailing twelve months GMAB reported a non-GAAP Earnings per Share(EPS) of 2.36. The EPS increased by 125.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 41.35% | ||
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| Debt/Equity | 0.02 |
GMAB Forecast & Estimates
27 analysts have analysed GMAB and the average price target is 28.4 USD. This implies a price decrease of -16.16% is expected in the next year compared to the current price of 33.88.
For the next year, analysts expect an EPS growth of 2.82% and a revenue growth 22.77% for GMAB
GMAB Ownership
GMAB Latest News, Press Relases and Analysis
About GMAB
Company Profile
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Company Info
GENMAB A/S -SP ADR
Carl Jacobsens Vej 30
Valby 1560 DK
CEO: Jan G. J. van de Winkel
Employees: 2681
Phone: 4570202728
GENMAB A/S -SP ADR / GMAB FAQ
What does GENMAB A/S -SP ADR do?
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
What is the current price of GMAB stock?
The current stock price of GMAB is 33.88 USD. The price increased by 2.36% in the last trading session.
What is the dividend status of GENMAB A/S -SP ADR?
GMAB does not pay a dividend.
How is the ChartMill rating for GENMAB A/S -SP ADR?
GMAB has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Which stock exchange lists GMAB stock?
GMAB stock is listed on the Nasdaq exchange.
Is GENMAB A/S -SP ADR (GMAB) expected to grow?
The Revenue of GENMAB A/S -SP ADR (GMAB) is expected to grow by 22.77% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of GMAB stock?
GENMAB A/S -SP ADR (GMAB) has a market capitalization of 20.87B USD. This makes GMAB a Large Cap stock.